Skip to content

Efficacy Of Prodovite® In Athletic Performance

Clinical Study On Prodovite® In Athletic Performance

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04734834
Acronym
VMP35SPORT
Enrollment
150
Registered
2021-02-02
Start date
2020-10-01
Completion date
2022-10-30
Last updated
2021-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SPORTS NUTRITION

Keywords

Prodovite® VMP35, 90-Day, 150 Subjects, Double-Blind, Placebo-Control Study, Endurance Athletic Performance, Adverse Events Monitoring

Brief summary

A novel patent-pending Prodovite® VMP35 Multi-Nutrient-Complex (MNC), a vitamin, mineral, and phytonutrient encapsulated liquid formulation, was prepared using a novel proprietary SK713 SLP multi-lamellar non-GMO phospholipid nutrient absorption/delivery technology in a state-of-the-art multistep cGMP and NSF-certified manufacturing facility. This developmental technology is biodegradable and biocompatible. Preliminary study in our laboratory demonstrated the efficacy of Prodovite® VMP35 in Sports Nutrition. The investigators hypothesize that Prodovite® VMP35 supplement will enhance strength, endurance, and athletic performance; and improve energy output, lean-body muscle mass, increase exercise tolerance, recovery, and improve anabolic parameters in healthy human subjects. The aim of this randomized double-blind placebo-controlled study is to evaluate the effect of oral supplementation of Prodovite® VMP35 on the parameters. The investigators hypothesize that Prodovite® VMP35 supplementation will enhance all the athletic parameters and improve blood chemistry parameters in healthy human subjects. Accordingly, 150 healthy male and female subjects will be randomly assigned to receive either Prodovite® VMP35 or placebo in the form of single dose sealed containers for 90 consecutive days and muscle strength, endurance, speed, anabolic/catabolic parameters and muscle mass will be evaluated by dual energy X-ray absorptiometry (DEXA), hand-grip strength test, cycle ergometer test, spirometer assessment and assay of Blood chemistry and serum biomarkers will be evaluated before and after intervention.

Detailed description

Higher level athletic performance induces greater demands on nutrient and oxygen utilization and hydration. Consistent performance-induced chronic resource depletion from demands of this level can induce an increasing anaerobic, hypoxic/acidic environment, promoting anaerobic metabolic events (i.e. anaerobic glycolysis). Disorders arising from this depletion include chronic inflammation, cramps, and pain, and induce a defensive expenditure of alkalinizing buffers in hemoglobin (i.e. histidine), to prevent a dangerous lowering of blood pH. The physical demands of higher levels of athletic performance deplete biological resources predisposing a greater incidence of chronic problems such as cramps, inflammation, muscle injury and pain. A Phase 1 Pilot Validation Study was conducted in three healthy young trained male athletes (Age: 32-39 years) over a period of 90 consecutive days, with a 2-week intermediate evaluation1. Subjects consumed 30 mL (1-ounce) of Prodovite® VMP35, a World Anti-Doping Association (WADA) compliant iron-free liquid Prodovite® VMP35 vitamin, mineral and phytonutrient complex (MNC) on an empty stomach before engaging in a rigorous exercise regimen in the morning. They consumed another ounce of the Prodovite® VMP35 again mid-afternoon of the same day. Total blood chemistry including free and bound testosterone levels, as well as changes in their exercise performance activities were closely monitored and recorded prior to consuming the Prodovite® VMP35, during the intermediate 2-week evaluation, and then again at the end of the study period. In the 2-week Phase 1 evaluation, 1 ounce of Prodovite® VMP35 taken within 30 minutes before engaging in a rigorous exercise regimen, induced dramatic improvements in athletic exercise performance. Following Prodovite® VMP35 supplementation, physiological health including physical strength, stamina, respiratory parameters, energy level, and sleep quality increased, and blood chemistry parameters were improved. Before Prodovite® VMP35 intake, one subject was struggling with 270 lbs. for 4 reps on the banded reverse Hack Squat, while after supplementation, subject achieved 270 lb.s for 10 reps; rested, then the very next set increased to 320 lbs. for 10 reps. The set after that (the 3rd and final set of that exercise), weight increased again to 360 lbs. for 8 reps. In another subject on the same equipment, pre-Prodovite® VMP35 supplementation, the squat result was 405 lbs. for 10 reps, while post-Prodovite® VMP35 supplementation, the squat increased significantly to 455 lbs. for 6 reps. Pre-Prodovite® VMP35 intake, one exercise in particular, the subject was able to perform the banded reverse hack squat with 160 lbs for one set of 8 reps. After Prodovite® VMP35 intake, the subject increased squat performance to 180 lbs. for 2 sets of 10 reps. On the Hammer Strength banded incline chest press, pre-Prodovite® VMP35, subject's working weight sets were 160 lbs. Post-Prodovite® VMP35 sets increased to 180 lbs. Another increase in strength was experienced in banded Hammer Strength incline press. Pre-VMP35, Subject was doing 180 lbs. for 10 reps, which was increased to 230 lbs. for 10 reps post Prodovite® VMP35. On side lateral dumbbell raises subject's working weight increased from 20 lbs. Pre-Prodovite® VMP35 to 25 lbs. Post- Prodovite® VMP35 supplementation, subjects were able to push a little harder and achieve extra reps with shorter rest periods. Overall, a significant increase in strength was noticed in all subjects and all subjects experienced shorter recovery time between sets and post-workout. Based on these encouraging data, investigators propose to conduct the following full-blown investigation. This pilot investigation inspired our team to conduct a randomized placebo-controlled, double-blind investigation in 150 volunteers (age: 18-74 years) over a period of 90 consecutive days. A statistician will be involved in this project. Body weight, body mass index (BMI), waist circumference, blood chemistry, blood pressure and heart rate, body and hand grip strength, speed and endurance studies including open circuit spirometry-based assessment of pulmonary function will be assessed. Other parameters to be evaluated include oxygen consumption, CO2 production and metabolic parameters, VO2 max, respiratory exchange ratio (RER), anaerobic threshold, ventilatory equivalents for oxygen (VE/V02) and exhaled carbon dioxide (VE/VC02). Subjects will participate in completed maximal graded exercise tests (GXT) on a treadmill or in set distance open-field sprints using open-circuit spirometry. Lower and Upper Body Strength will be evaluated. E-Diary will be provided to all participants. Survey Monkey program will be provided to all subjects and regularly updated by all study participants daily and endorsed by the Principal Investigator and Sub-Investigators.

Interventions

DIETARY_SUPPLEMENTProdovite® VMP35

Efficacy of Prodovite® VMP35 will be Assessed as Compared to Placebo

Sponsors

Victory Nutrition International, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

A double-blind placebo-controlled investigation in 150 subjects,

Intervention model description

A double-blind placebo-controlled investigation to evaluate the efficacy of Prodovite® VMP35 in Boosting Athletic Performance in Athletes

Eligibility

Sex/Gender
ALL
Age
18 Years to 74 Years
Healthy volunteers
Yes

Inclusion criteria

1. Agrees to written as well as audio-visual informed consent 2. Ability to understand the risks/benefits of the study protocol 3. Healthy male and female, human subjects 18-74 years of age 4. Subjects experienced with at least six months of regular athletic performance training

Exclusion criteria

1. Uncooperative Subjects 2. Subjects with chronic illness (diabetes, cardiovascular disease, cancer, arthritis, etc) or those on prescription medication excluded (except for birth control pills) 3. Any conditions that prevent the subject from participating in physical activities.

Design outcomes

Primary

MeasureTime frameDescription
Respiratory Exchange Ratio (RER) (as part of Endurance Assessment)Over the period of 90 consecutive daysA Cycle Ergometer will be used for measuring Respiratory Exchange Ratio (RER) in both placebo and Prodovite® groups
Maximum Power Output (W) (as part of Endurance Assessment)Over the period of 90 consecutive daysA Cycle Ergometer will be used for measuring Maximum Power Output (W) in both placebo and Prodovite® groups
VO2 Max (L.Min-1) (as part of Endurance Assessment)Over the period of 90 consecutive daysA Cycle Ergometer will be used for measuring VO2 Max (L.Min-1) in both placebo and Prodovite® groups
Total Cholesterol (mg/dL)Over the period of 90 consecutive daysTotal Cholesterol (mg/dL) in both placebo and Prodovite® groups
Total Testosterone (ng/dL)Over the period of 90 consecutive daysTotal Testosterone (ng/dL) in both placebo and Prodovite® groups
Blood Pressure (mm Hg)Over the period of 90 consecutive daysBlood Pressure including Systolic (mm Hg) and Diastolic Blood pressure (mm Hg) will be measured in both placebo and Prodovite® groups
Body Weight (Kg)Over the period of 90 consecutive daysBody Weight (Kg) will be measured in both placebo and Prodovite® groups
Height (m)Over the period of 90 consecutive daysHeight (m) will be measured in both placebo and Prodovite® groups
Body Mass Index (kg/m^2)Over the period of 90 consecutive daysBody Mass Index (kg/m\^2) will be measured in both placebo and Prodovite® groups
Body circumference (in cm)Over the period of 90 consecutive daysBody Circumference \[arm (cm)\], \[waist (cm)\], \[hip (cm)\], and \[calf (cm)\] will be measured in both placebo and Prodovite® groups
Waist Hip RatioOver the period of 90 consecutive daysWaist Hip Ratio will be measured in both placebo and Prodovite® groups
Knee-Heel Length (cm)Over the period of 90 consecutive daysKnee-Heel Length (cm) will be measured in both placebo and Prodovite® groups
Percent Body Fat (%)Over the period of 90 consecutive daysPercent Body Fat (%) Measurement by Dual Energy X-Ray Absorptiometry (DEXA) in both placebo and Prodovite® groups
Bone Mineral Density (g/cm2)Over the period of 90 consecutive daysBone Mineral Density (g/cm2) Measurement by Dual Energy X-Ray Absorptiometry (DEXA) in both placebo and Prodovite® groups
Fat Free Mass [Body fat percent (%) x scale weight = fat mass]Over the period of 90 consecutive daysFat Free Mass \[Body fat percent (%) x scale weight = fat mass\] Measurement by Dual Energy X-Ray Absorptiometry (DEXA) in both placebo and Prodovite® groups
Lean Body Mass (lbs)[scale weight - fat mass = lean body mass]Over the period of 90 consecutive daysLean Body Mass (lbs)\[scale weight - fat mass = lean body mass\] Measurement by Dual Energy X-Ray Absorptiometry (DEXA) in both placebo and Prodovite® groups
In-Body Electrical Impedance ValueOver the period of 90 consecutive daysBody Composition Analysis (In-Body Electrical Impedance) in both placebo and Prodovite® groups
Hand-Grip Strength (lb)Over the period of 90 consecutive daysDigital Hand Dynamometer will be used for assessing Hand-Grip Strength (lb) \[Percent (%) Change\] in both placebo and Prodovite® groups
Strength Assessment (lb/reps)Over the period of 90 consecutive daysMaximum Push-Up Test for Assessing Upper Body Strength (lb/reps) in both placebo and Prodovite® groups

Secondary

MeasureTime frameDescription
Adverse Events MonitoringOver the period of 90 consecutive daysAdverse Events including headache, nausea, vomiting, diarrhea, rash, fever, muscle cramp and weight gain will be critically Monitored in Both Placebo- and Prodovite® Groups
Study ComplianceOver the period of 90 consecutive daysStudy Compliance including subject drop-outs and recording of supplement intake will be critically evaluated in Both Placebo- and Prodovite® Groups

Countries

United States

Contacts

Primary ContactBRUCE S MORRISON, DO
drmorrisonfm@gmail.com(215)947-9131
Backup ContactBerrnard W Downs
billd@vni.life2155639339

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026